• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

    3/14/25 8:35:00 AM ET
    $CGTX
    $COCP
    $FBLG
    $PDSB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGTX alert in real time by email

    NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing.

    REGISTER NOW AT: https://bit.ly/3DIWqav

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    Select companies are accepting 1x1 management meeting requests through March 18th.

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    March 13th

    PresentationTicker(s)
    Cognition Therapeutics, Inc.(NASDAQ:CGTX)
    Biophytis SA(OTC:BPTSY, FP: ALBPS))
    Avicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    Psy Therapeutics, Inc.Private
    Cocrystal Pharma, Inc.(NASDAQ:COCP)
    NervGen Pharma Corp.(OTCQB:NGENF, TSXV:NGEN)
    FibroBiologics, Inc.(NASDAQ:FBLG)
    Telescope Innovations Corp.(OTCQB:TELIF, CSE:TELI)
    Rafarma Pharmaceuticals, Inc.(OTC:RAFA)
    Izotropic Corporation(OTCQB:IZOZF, CSE:IZO)
    PDS Biotechnology Corporation(NASDAQ:PDSB)
    LadRx Corporation(OTCQB:LADX)
    Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    Hemostemix, Inc.(OTCQB:HMTXF, TSXV:HEM)



    About Virtual Investor Conferences
    ®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $CGTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CGTX
    $COCP
    $FBLG
    $PDSB

    CompanyDatePrice TargetRatingAnalyst
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    FibroBiologics Inc.
    $FBLG
    12/12/2024$12.00Buy
    Rodman & Renshaw
    FibroBiologics Inc.
    $FBLG
    10/30/2024$12.00Buy
    H.C. Wainwright
    FibroBiologics Inc.
    $FBLG
    9/24/2024$12.00Buy
    Maxim Group
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    PDS Biotechnology Corporation
    $PDSB
    11/1/2022$10.00Buy
    B. Riley Securities
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    4/18/2022Outperform
    Noble Capital Markets
    Cognition Therapeutics Inc.
    $CGTX
    11/3/2021$27.00Buy
    B. Riley Securities
    More analyst ratings

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

      Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, toda

      7/2/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

      PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer's Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. Christopher van Dyck, MD, stated, "This is an important milestone for the study and is a testament to the commitment of the investigators and site teams and a high level of interest from participants in an or

      7/1/25 7:30:23 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

      CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attr

      6/30/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Khoja Hamid bought $16,800 worth of shares (20,000 units at $0.84), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      5/27/25 5:56:53 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Lederman Seth bought $86,200 worth of shares (4,000 units at $21.55), increasing direct ownership by 80,000% to 4,005 units (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      5/15/25 5:08:40 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

      4 - PDS Biotechnology Corp (0001472091) (Issuer)

      3/3/25 4:45:42 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Khattar Jack A. was granted 34,000 shares, increasing direct ownership by 234% to 48,500 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:22:07 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wallace Peggy was granted 34,000 shares, increasing direct ownership by 65% to 86,461 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:21:38 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Richstone Ellen B was granted 34,000 shares, increasing direct ownership by 139% to 58,500 units (SEC Form 4)

      4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

      6/23/25 7:21:06 PM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    SEC Filings

    See more
    • FibroBiologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      7/3/25 4:03:02 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      7/2/25 7:06:11 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

      7/1/25 4:30:41 PM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cognition Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

      12/19/24 7:33:00 AM ET
      $CGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

      Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      12/12/24 8:54:24 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on FibroBiologics with a new price target

      H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      10/30/24 6:37:36 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Leadership Updates

    Live Leadership Updates

    See more
    • Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors

      Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of

      6/13/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

      6/9/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

      Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene Served on Celgene's Executive Committee and played a key leadership role in the BMS transaction, the integration of Celgene into BMS, and the divestiture of Otezla® to Amgen Appointment marks a key addition as Tonix readies for the potential approval of TNX-102 SL for the management of fibromyalgia next quarter CHATHAM, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical compa

      5/14/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Financials

    Live finance-specific insights

    See more
    • PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Trial-in-progress currently enrolling patients Conference call on Friday, May 23 at 8:00 a.m. ET to discuss ASCO abstract data sets PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced pub

      5/22/25 5:26:36 PM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

      In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Our oral pan-viral protease inhibitor CDI-988 is a potential breakthrough first-in-class treatment and prophylaxis for norovirus, a debilitating gastrointestinal infection that strikes millions globally each year," said Sam Lee, Ph.D., President and co-CEO of Cocrystal. "By precisely targ

      5/15/25 8:00:00 AM ET
      $COCP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m. Eastern Time. Conference Call Details Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes prior to ca

      5/7/25 8:00:00 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care